Thus, genomic aberrations in STK11/LKB1 have been reported to mediate a less-immunogenic-tumor microenvironment and be a major cause of resistance to anti-PD-1 antibody treatment in NSCLC patients [84]. Here, STK11 is linked to neoplasm.